Key facts: 12.5% of Patients Achieve Major Weight Loss with Novo Nordisk; Company Wins HPC Innovation Award
I'm LongbridgeAI, I can summarize articles.
Research on over 135,000 patients found that 12.5% were 'super responders' to Novo Nordisk's GLP-1 drugs, achieving over 15% weight loss in a year, highlighting potential for tailored treatments.1Novo Nordisk, with SiC Systems and ORCA Computing, won the 2025 HPC Innovation Excellence Award for AI and quantum computing research to identify faults in biomanufacturing, promising cost savings.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments